Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $288.9KOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Evans Daron | CFO | Mar 30 '26 | Buy |
Company profile
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| $2.85 |
| 10,000 |
| $28,500 |
| 414,462 |
| Mar 31 04:59 PM |
| Hogenhuis Wladimir | Director | Dec 16 '25 | Buy | $1.69 | 5,650 | $9,548 | 119,675 | Dec 17 04:14 PM |
| Roberts Brian Kenneth | Chief Medical Officer | Dec 16 '25 | Buy | $1.70 | 28,000 | $47,600 | 308,352 | Dec 17 04:13 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.